Abstract CT054: The development of a personalized autologous clonal neoantigen T cell therapy for the treatment of solid cancer using the VELOSTM manufacturing platform generates highly potent and reactive CD8+ and CD4+ T cells for clinical use
Henrieta Fraser, Edward Samuel, Fong Chun Chan(BC Cancer Agency), Gareth A. Wilson(The Francis Crick Institute), Sam Jide-Banwo, Samra Turajlic(Royal Marsden NHS Foundation Trust), Lyra Del Rosio(Royal Marsden NHS Foundation Trust), Mariam Jamal‐Hanjani(CRUK Lung Cancer Centre of Excellence), Luke Goodsell, Iraj Ali, Sarah Thirkell, Shreenal Patel, Rebecca Pike, Max Salm(Cancer Research UK), Evi Rologi, Hollie Bartley, Asiya Arshad, Martin Förster, Farah Islam(London Cancer), Andrew J. Hayes(Royal Marsden NHS Foundation Trust), Michał P. Pruchniak, Andrew W. Craig(Queen's University), Jennine Mootien, David Lawrence(University College London Hospitals NHS Foundation Trust), Jane Robertson(Cancer Research UK), Karl S. Peggs(Royal London Hospital), Katy Newton, Mark W. Lowdell(Royal Free London NHS Foundation Trust)
Cited by 0
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Resolving genetic heterogeneity in cancer
|Nature Reviews Genetics|2019|689